Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: Do we have a winner?

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 12, 2015, Pages 1333-1344

  Serebruany, Victor L ^a,b   Tomek, Ales ^c   Pokov, Alex N ^a   Kim, Moo Hyun ^d  

^a Osler Medical Center   (United States)

^b Johns Hopkins   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Dong A University   (South Korea)

Author keywords

Clinical trials; Clopidogrel; Creatinine clearance; Drug safety; Prasugrel; Renal function; Ticagrelor; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; CYSTATIN C; PRASUGREL; TICAGRELOR; URIC ACID; VORAPAXAR; ADENOSINE; ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE; TICLOPIDINE;

CARDIOVASCULAR MORTALITY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG CONTRAINDICATION; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MODERATE RENAL IMPAIRMENT; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PUBLICATION; REVIEW; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION; ACUTE CORONARY SYNDROME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; COMPLICATION; HEMORRHAGE; PATIENT SELECTION; RENAL INSUFFICIENCY;

ACUTE CORONARY SYNDROME; ADENOSINE; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HUMANS; LACTONES; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PYRIDINES; RENAL INSUFFICIENCY; TICLOPIDINE;

EID: 84948572306     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1101343     Document Type: Review

References (40)

1. Baber U, Auguste U. Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome. Curr Cardiol Rep. 2013; 15: 386.
2. Narala KR, Hassan S, LaLonde TA, et al. Management of coronary atherosclerosis and acute coronary syndromes in patients with chronic kidney disease. Curr Probl Cardiol. 2013; 38: 165-206.
3. Breet NJ, De Jong C, Bos WJ, et al. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thromb Haemost. 2014; 112: 1174-1181.
4. Htun P, Kan T, Mueller E, et al. Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end stage renal disease. Results of a pilot study. Thromb Haemost. 2014; 111: 662-669.
5. Tentzeris I, Siller-Matula J, Farhan S, et al. Platelet function variability and non-genetic causes. Thromb Haemost. 2011; 105 (Suppl 1): S60-6.
6. Jain N, Hedayati SS, Sarode R, et al. Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence? Clin J Am Soc Nephrol. 2013; 8: 665-674.
7. Gabrielli A, Bouatou Y, Saudan P. Use of antiplatelet agents in patients with chronic kidney disease: what is the evidence?. Rev Med Suisse. 2014; 10: 487-490.
8. Palmer SC, Di Micco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2013; 2: CD008834.
9. Gremmel T, Müller M, Steiner S, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013; 28: 2116-2122.
10. Park SH, Kim W, Park CS, et al. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009; 104: 1292-1295.
11. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996; 348: 1329-1339.
12. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med. 2001; 345: 494-502.
13. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366 (9497): 1607-1621.
14. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352: 1179-1189.
15. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-1717.
16. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411-2420.
17. Keltai M, Tonelli M, Mann JF, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007; 14: 312-318.
18. Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the clopidogrel for the reduction of events during observation (CREDO) trial. Am Heart J. 2008; 155: 687-693.
19. Ahmed S, Michael Gibson C, et al. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thrombolys. 2011; 31: 493-500.
20. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015.
21. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012; 367: 1297-1309.
22. Wrishko RE, Ernest CS 2nd, Small DS, et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009; 49: 984-998.
23. Food and Drug Administration. Briefing document, February 3, 2009 meeting of FDA Cardiovascular and Renal Drugs Advisory Committee on Prasugrel. [. cited 2015 Jan 16]. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm181185.pdf
24. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 61: 1045-1057.
25. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-1800.
26. Serebruany VL. Ticagrelor shift from PLATO to PEGASUS: vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. Int J Cardiol. 2015; 201: 508-512.
27. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010; 122: 1056-1067.
28. Akerblom A, Wallentin L, Siegbahn A, et al. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients-results from the PLATelet inhibition and patient outcomes (PLATO) study. Am Heart J. 2012; 164: 728-734.
29. Åkerblom A, Wallentin L, Larsson A, et al. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet inhibition and patient outcomes (PLATO) study. Clin Chem. 2013; 59: 1369-1375.
30. Akerblom A, Eriksson N, Wallentin L, et al. Polymorphism of the cystatin C gene in patients with acute coronary syndromes: results from the PLATelet inhibition and patient outcomes study. Am Heart J. 2014; 168: 96-102.
31. Akerblom Å, Wallentin L, Siegbahn A, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clin Chem. 2012; 58: 190-199.
32. The FDA ticagrelor review of complete response. Available for download at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000MedR.pdf. Assessed January 16, 2015
33. NDA 294-886. Cross-discipline Team Leader review on Vorapaxar. April 18th, 2014. [. cited 2015 Jan 17]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/204886Orig1s000SumR.pdf
34. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404-1413.
35. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012; 366: 20-33.
36. Serebruany VL. Redesigning TRACER after TRITON. Intern J Cardiol. 2015; 197: 44-47.
37. Kosoglou T, Kraft WK, Kumar B, et al. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012; 68: 1049-1056.
38. Chiang FT, Shyu KG, Wu CJ, et al. Predictors of 1-year outcomes in the Taiwan acute coronary syndrome full spectrum registry. J Formos Med Assoc. 2014; 113: 794-802.
39. Blicher TM, Hommel K, Kristensen SL, et al. Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. J Am Heart Assoc. 2014; 3: e001116.
40. Jeong KH, Cho JH, Woo JS, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015; S0272-6386: 01533-9.